Print
News from the FDA: First-line treatment and biosimilars for prostate cancer
https://www.facingourrisk.org/XRAY/news-from-FDA-PrCa-Aug-2024
Full article: https://www.fda.gov
The FDA recently approved a first-line treatment for non-metastatic, castration-sensitive prostate cancer. Approval was also given to two new drugs known as biosimilars that can be used in place of two already approved biologics to prevent bone weakening, pain or fractures that may occur from certain hormone therapies or from cancer that has spread to the bone. (Posted 9/10/24)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What treatment options are available for my stage and type of prostate cancer?
- Are you tracking my PSA levels? Have they been stable or are they rising?
- Am I taking medication that can affect my bone health?
- Should I have a bone density test to see if my bones are healthy?
- What can I do to improve my bone health during and after treatment?
- Is there an option or advantage for me to switch to an available biosimilar?
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.